COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
 
Home   
Share  
Tweet
  StudiesStudies
  Global AdoptionAdoption
  Submit FeedbackFeedback
00.250.50.7511.251.51.752+Rocco (RCT)5.04[0.24-1e+02]ICU2/1940/198RRCITreatmentControlCadegiani0.12[0.01-2.52]death0/3572/137Elalfy0.13[0.06-0.27]viral+7/6244/51CT​1Silva (SB RCT)0.74[0.14-3.85]viral+2313Rossignol (DB RCT)3.06[0.13-74.64]death1/1840/195Tau​2 = 1.61; I​2 = 63.5%Early treatment0.51[0.12-2.27]10/82046/59449% improvementBlum (DB RCT)0.33[0.07-1.50]death2/256/25RRCITreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment0.33[0.07-1.50]2/256/2567% improvementAll studies0.42[0.14-1.30]12/84552/61958% improvement6 nitazoxanide COVID-19 studiesc19nitazoxanide.com 5/4/211 CT: study uses combined treatmentTau​2 = 0.94; I​2 = 55.6%; Z = 1.51 (p = 0.066)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Cadegiani0.12[0.01-2.52]0/3572/137RRCITreatmentControlRossignol (DB RCT)3.06[0.13-74.64]1/1840/195Tau​2 = 2.67; I​2 = 51.4%Early treatment0.59[0.02-13.78]1/5412/33241% improvementBlum (DB RCT)0.33[0.07-1.50]2/256/25RRCITreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment0.33[0.07-1.50]2/256/2567% improvementAll studies0.40[0.10-1.58]3/5668/35760% improvement3 nitazoxanide COVID-19 mortality resultsc19nitazoxanide.com 5/4/21Tau​2 = 0.17; I​2 = 9.3%; Z = 1.31 (p = 0.096)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Rocco (RCT)5.04[0.24-1e+02]2/1940/198RRCITreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment5.04[0.24-1e+02]2/1940/198-404% improvementAll studies5.04[0.24-1e+02]2/1940/198-404% improvement1 nitazoxanide COVID-19 ICU resultc19nitazoxanide.com 5/4/21Tau​2 = 0.00; I​2 = 0.0%; Z = 1.05 (p = 0.15)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Rocco (RCT)1.02[0.30-3.47]5/1945/198RRCITreatmentControlCadegiani0.01[0.00-0.17]0/35727/137Rossignol (DB RCT)0.21[0.03-1.80]1/1845/195Tau​2 = 3.67; I​2 = 78.3%Early treatment0.17[0.01-2.00]6/73537/53083% improvementBlum (DB RCT)0.68[0.46-0.99]2525RRCITreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment0.68[0.46-0.99]0/250/2532% improvementAll studies0.35[0.10-1.22]6/76037/55565% improvement4 nitazoxanide COVID-19 hospitalization resultsc19nitazoxanide.com 5/4/21Tau​2 = 1.01; I​2 = 70.3%; Z = 1.64 (p = 0.05)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Rocco (RCT)5.04[0.24-1e+02]ICU2/1940/198RRCITreatmentControlCadegiani0.12[0.01-2.52]death0/3572/137Rossignol (DB RCT)3.06[0.13-74.64]death1/1840/195Tau​2 = 1.71; I​2 = 40.9%Early treatment1.21[0.12-12.26]3/7352/530-21% improvementBlum (DB RCT)0.33[0.07-1.50]death2/256/25RRCITreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment0.33[0.07-1.50]2/256/2567% improvementAll studies0.69[0.15-3.29]5/7608/55531% improvement4 nitazoxanide COVID-19 serious outcomesc19nitazoxanide.com 5/4/21Tau​2 = 0.88; I​2 = 33.9%; Z = 0.46 (p = 0.32)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Rocco (RCT)5.04[0.24-1e+02]ICU2/1940/198RRCITreatmentControlRocco (RCT)1.02[0.30-3.47]hosp.5/1945/198Rocco (RCT)1.16[0.84-1.59]no recov.59/19452/198Rocco (RCT)0.88[0.79-0.97]viral+194198Rocco (RCT)0.86[0.77-0.96]viral+136/194162/198Cadegiani0.12[0.01-2.52]death0/3572/137Cadegiani0.03[0.00-0.51]ventilation0/3579/137Cadegiani0.01[0.00-0.17]hosp.0/35727/137Elalfy0.13[0.06-0.27]viral+7/6244/51CT​1Elalfy0.42[0.31-0.56]viral+26/6251/51CT​1Silva (SB RCT)0.74[0.14-3.85]viral+2313Silva (SB RCT)0.62[0.39-0.97]viral+12/2311/13Rossignol (DB RCT)3.06[0.13-74.64]death1/1840/195Rossignol (DB RCT)0.21[0.03-1.80]hosp.1/1845/195Rossignol (DB RCT)0.15[0.02-1.22]severe case1/1847/195Rossignol (DB RCT)0.16[0.02-1.29]severe case1/1127/126Blum (DB RCT)0.33[0.07-1.50]death2/256/25Blum (DB RCT)0.68[0.46-0.99]hosp. time2525Blum (DB RCT)0.10[0.01-1.78]viral+0/234/19nitazoxanide COVID-19 outcomesc19nitazoxanide.com 5/4/21Lower RiskIncreased Risk
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary; multiple approaches are required to cover all people and all existing and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit